From the bench to the bedside: emerging new treatments in multiple myeloma
- 31 December 2007
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 20 (4), 797-816
- https://doi.org/10.1016/j.beha.2007.09.008
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growthBritish Journal of Haematology, 2007
- Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myelomaHematology, 2007
- The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBritish Journal of Haematology, 2007
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2006
- Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90Proceedings of the National Academy of Sciences of the United States of America, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994